Quote
781.49
-11.77 (-1.48%)
We have scored 86 news catalysts on REGN (REGN) over the past 12 months. Coverage across the window leans negative (average ticker sentiment −0.22). Most of the impact sits in price momentum and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
780.98–800.22
Open
800.00
Prev close
793.26
Volume
444K
Avg volume
—
Dividend
—
IPO
—
No scored news tagged REGN or its network in the window yet.
Show more REGN articles →Analysts publish price targets on REGN, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
23 analyst price targets from $641 to $1,030
as of 2026-09-12
The market is within 0% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about REGN — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of REGN, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for REGN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the 52nd percentile of 23 published models, almost exactly matching the median target, meaning the market broadly endorses the middle view and explicitly refuses to pay for either the steep bull cases or the deep bear case.
What the disagreement turns on
Whether Regeneron can replace declining Eylea sales and the failed Fianlimab melanoma opportunity with its obesity pipeline and other oncology indications, a question that unit volume tracking can partially answer but that ultimately depends on clinical trial readouts no wired dataset can capture.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
